Protease activated receptor 2 (PAR2) reduces pro-inflammatory cytokine production in bronchial epithelial cells

Bailo, Mariarca; Dunning, L.; Brzeszczyska, J.; McIntosh, K.; Plevin, R.; Martin, S. L.; Sergeant, G. P.; Goodyear, C. S.; Litherland, G. S.; Lockhart, J. C.; Crilly, A.

Published: 24/08/2020

Document Version
Peer reviewed version

Link to publication on the UWS Academic Portal

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in the UWS Academic Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
If you believe that this document breaches copyright please contact pure@uws.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Protease activated receptor 2 (PAR2) antagonism reduce pro-inflammatory cytokine production in bronchial epithelial cells

PAR2 is a G-protein coupled receptor which modulate inflammation via pro-inflammatory cytokine release. Chronic obstructive pulmonary disease (COPD) is associated with an abnormal inflammatory response of the lungs. The aim of this study was to investigate a putative role for PAR2 in COPD.

Expression of PAR2 and was evaluated in in primary human bronchial epithelial cells derived from healthy controls and COPD patients (HBECs & DHBECs respectively) and bronchial epithelial cell lines (BEAS-2B) by immunofluorescence. Levels of secreted IL-6 and IL-8 were evaluated by ELISA. The role of PAR2 in BEAS-2B was investigated using the PAR2 agonist 2-Furoyl-LIGRLO-amide and the antagonist AZ8838.

Immunofluorescent microscopy showed HBECs, DHBECs and BEAS-2B express PAR2. Evaluation of spontaneous cytokine secretion revealed that both IL-6 and IL-8 were significantly increased (P<0.01) in DHBECs compared to HBECs and BEAS-2B. Initial studies demonstrate inhibition of PAR2 activation in BEAS-2B by AZ8838 significantly reduced IL-8 (24 h) and IL-6 (48 h) secretion.

This study used a recently developed antagonist to demonstrate a role for PAR2 in regulation of pro-inflammatory cytokine release in bronchial epithelial cells. Since increased PAR2 activation is a feature of several inflammatory disease, it may contribute to the abnormal response in COPD.